Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?

Immunotherapy. 2014;6(10):1017-20. doi: 10.2217/imt.14.87.

Author

Lei Zheng¹

Affiliation

¹ Departments of Oncology & Surgery, The Sidney Kimmel Cancer Center, & the Skip Viragh Center for Pancreatic Cancer Research & Clinical Care, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 488, Baltimore, MD 21231, USA.

No abstract available

Keywords: PD-1; PD-L1; immunotherapy; pancreatic cancer; tertiary lymphoid aggregates; vaccine.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cancer Vaccines / immunology*
Humans
Immune Tolerance / immunology*
Immunotherapy / methods*
Pancreatic Neoplasms / immunology*
Pancreatic Neoplasms / therapy

Substances

Cancer Vaccines

Grants and funding